Dr. Frohna is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Marseille, France
Solana Beach, CA 92075- Is this information wrong?
Summary
- Paul Frohna, MD, PhD, is a researcher in Marseille, France. He received his medical degree from Georgetown University School of Medicine and has been doing clinical research for 20 years. He does not see patients. He is experienced in translational medicine and clinical trials in immuno-oncology, immunology, multiple sclerosis, Alzheimer's disease and regenerative medicine.
Education & Training
- University of Texas at Austin Dell Medical SchoolInternship, Internal Medicine, 2000 - 2001
- Georgetown University School of MedicineClass of 2000
Clinical Trials
- U.S. Study of Fibrocaps in Surgical Hemostasis Start of enrollment: 2010 Dec 01
- A Study of Fibrocaps in Liver Surgery in the Netherlands Start of enrollment: 2010 Dec 01
- A Study of Fibrocaps™ in Surgical Bleeding Start of enrollment: 2012 May 21
- Join now to see all
Publications & Presentations
PubMed
- 121 citationsSafety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, ...Jeffrey A. Cohen, Douglas L. Arnold, Giancarlo Comi, Amit Bar-Or, Sheila Gujrathi
The Lancet. Neurology. 2016-04-01 - 30 citationsEfficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study:Jeffrey A. Cohen, Giancarlo Comi, Douglas L. Arnold, Amit Bar-Or, Krzysztof Selmaj
Multiple Sclerosis. 2019-08-01 - 151 citationsRPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.Ikuo Hirano, Margaret H. Collins, Yehudith Assouline-Dayan, Larry Evans, Sandeep K. Gupta
Gastroenterology. 2019-02-01
Press Mentions
- ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual MeetingNovember 11th, 2022
- Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of ICT01 plus Pembrolizumab in the EVICTION Trial at ESMO Congress 2022September 10th, 2022
- ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021September 17th, 2021
- Join now to see all
External Links
- Frohna Biotech Consultinghttp://www.frohnabiotechconsulting.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: